Name:
Safety and efficacy darolutamide in Black/African-American patients in the ARAMIS study
Description:
Safety and efficacy darolutamide in Black/African-American patients in the ARAMIS study
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/ebc0397e-2ffe-475d-997d-a53b17520f9b/videoscrubberimages/Scrubber_1.jpg
Duration:
T00H01M46S
Embed URL:
https://stream.cadmore.media/player/ebc0397e-2ffe-475d-997d-a53b17520f9b
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/ebc0397e-2ffe-475d-997d-a53b17520f9b/FSG - ARAMIS - Animation V07 (1).mp4?sv=2019-02-02&sr=c&sig=Y4HD2D41qfAeWT%2F1mQTndZpHQMGjkRT9r1t5pQYcroc%3D&st=2025-01-22T20%3A32%3A47Z&se=2025-01-22T22%3A37%3A47Z&sp=r
Upload Date:
2023-09-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
Darolutamide is an oral treatment for patients with non-metastatic, castration-resistant prostate cancer, or nmCRPC. This stage of prostate cancer has not spread to other body parts. Prostate specific antigen, or PSA levels, continue to rise despite surgery or the use of hormone therapy, androgen-deprivation therapy, or ADT, to lower testosterone levels.
Black and African-American patients experience higher incidence rates of prostate cancer – and are more likely to die from the disease, versus other groups.
Darolutamide, plus ADT, increased the time that Black and African-American patients were free from cancer spreading. Darolutamide also helped patients live longer. At 3 years, 100% of Black and African-American patients receiving darolutamide were alive, versus 71% for placebo. Darolutamide also delayed time to first chemotherapy and time to progression of PSA.
The safety profile of darolutamide in Black and African American patients was consistent with all patients in ARAMIS. Fewer adverse events and discontinuations due to adverse events were reported with darolutamide versus placebo.
Darolutamide is effective and well-tolerated in Black and African-American patients with nmCRPC, consistent with the overall ARAMIS population. These results may help guide treatment decisions in a population that is disproportionately affected by prostate cancer and often underrepresented in clinical trials.
